Fig. 2From: Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is nowMedian PFS of lapatinib-resistant and -naive patients after later-line treatment with pyrotinib in advanced stage (mPFS, median progression-free survival; NA, not applicable)Back to article page